Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: A retrospective cohort study

Anna R. Broder; Wenzhu Bi Mowrey; Mimi Kim; Irina Murakhovskaya; Henny H. Billett; Joel Neugarten; Karen H. Costenbader; Chaim Putterman

doi:10.1093/rheumatology/kev423

Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: A retrospective cohort study

Anna R. Broder, Wenzhu Bi Mowrey, Mimi Kim, Irina Murakhovskaya, Henny H. Billett, Joel Neugarten, Karen H. Costenbader, Chaim Putterman

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Objective. To investigate the association between the presence of aPL and/or LA and all-cause mortality among end-stage renal disease (ESRD) patients with and without SLE. Methods. We included ESRD patients>18 years old followed at an urban tertiary care centre between 1 January 2006 and 31 January 2014 who had aPL measured at least once after initiating haemodialysis. All SLE patients met ACR/SLICC criteria. APL/LA+ was defined as aCL IgG or IgM>40 IU, anti-b2glycoprotein1 IgG or IgM≫40 IU or LA+. Deaths as at 31 January 2014 were captured in the linked National Death Index data. Time to death was defined from the first aPL measurement. Results. We included 34 SLE ESRD and 64 non-SLE ESRD patients; 30 patients died during the study period. SLE ESRD patients were younger [40.4 (12.5) vs 51.9 (18.1) years, P = 0.001] and more were women (88.2% vs 54.7%, P

Original language	English (US)
Pages (from-to)	817-825
Number of pages	9
Journal	Rheumatology
Volume	55
Issue number	5
DOIs	https://doi.org/10.1093/rheumatology/kev423
State	Published - May 1 2016

Fingerprint

Keywords

Antiphospholipid antibodies
End stage
Haemodialysis
Lupus nephritis
Renal disease
Systemic lupus erythematosus

ASJC Scopus subject areas

Rheumatology
Pharmacology (medical)

Cite this

Broder, A. R., Mowrey, W. B., Kim, M., Murakhovskaya, I., Billett, H. H., Neugarten, J., Costenbader, K. H., & Putterman, C. (2016). Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: A retrospective cohort study. Rheumatology, 55(5), 817-825. https://doi.org/10.1093/rheumatology/kev423

Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE : A retrospective cohort study. / Broder, Anna R.; Mowrey, Wenzhu Bi ; Kim, Mimi; Murakhovskaya, Irina; Billett, Henny H.; Neugarten, Joel; Costenbader, Karen H.; Putterman, Chaim.

In: Rheumatology, Vol. 55, No. 5, 01.05.2016, p. 817-825.

Research output: Contribution to journal › Article

Broder, Anna R. ; Mowrey, Wenzhu Bi ; Kim, Mimi ; Murakhovskaya, Irina ; Billett, Henny H. ; Neugarten, Joel ; Costenbader, Karen H. ; Putterman, Chaim. / Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE : A retrospective cohort study. In: Rheumatology. 2016 ; Vol. 55, No. 5. pp. 817-825.

@article{13ccfd7d143949e2802d447683ab1c4f,

title = "Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: A retrospective cohort study",

abstract = "Objective. To investigate the association between the presence of aPL and/or LA and all-cause mortality among end-stage renal disease (ESRD) patients with and without SLE. Methods. We included ESRD patients>18 years old followed at an urban tertiary care centre between 1 January 2006 and 31 January 2014 who had aPL measured at least once after initiating haemodialysis. All SLE patients met ACR/SLICC criteria. APL/LA+ was defined as aCL IgG or IgM>40 IU, anti-b2glycoprotein1 IgG or IgM≫40 IU or LA+. Deaths as at 31 January 2014 were captured in the linked National Death Index data. Time to death was defined from the first aPL measurement. Results. We included 34 SLE ESRD and 64 non-SLE ESRD patients; 30 patients died during the study period. SLE ESRD patients were younger [40.4 (12.5) vs 51.9 (18.1) years, P = 0.001] and more were women (88.2% vs 54.7%, P",

keywords = "Antiphospholipid antibodies, End stage, Haemodialysis, Lupus nephritis, Renal disease, Systemic lupus erythematosus",

author = "Broder, {Anna R.} and Mowrey, {Wenzhu Bi} and Mimi Kim and Irina Murakhovskaya and Billett, {Henny H.} and Joel Neugarten and Costenbader, {Karen H.} and Chaim Putterman",

year = "2016",

month = may

day = "1",

doi = "10.1093/rheumatology/kev423",

language = "English (US)",

volume = "55",

pages = "817--825",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE

T2 - A retrospective cohort study

AU - Broder, Anna R.

AU - Mowrey, Wenzhu Bi

AU - Kim, Mimi

AU - Murakhovskaya, Irina

AU - Billett, Henny H.

AU - Neugarten, Joel

AU - Costenbader, Karen H.

AU - Putterman, Chaim

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objective. To investigate the association between the presence of aPL and/or LA and all-cause mortality among end-stage renal disease (ESRD) patients with and without SLE. Methods. We included ESRD patients>18 years old followed at an urban tertiary care centre between 1 January 2006 and 31 January 2014 who had aPL measured at least once after initiating haemodialysis. All SLE patients met ACR/SLICC criteria. APL/LA+ was defined as aCL IgG or IgM>40 IU, anti-b2glycoprotein1 IgG or IgM≫40 IU or LA+. Deaths as at 31 January 2014 were captured in the linked National Death Index data. Time to death was defined from the first aPL measurement. Results. We included 34 SLE ESRD and 64 non-SLE ESRD patients; 30 patients died during the study period. SLE ESRD patients were younger [40.4 (12.5) vs 51.9 (18.1) years, P = 0.001] and more were women (88.2% vs 54.7%, P

AB - Objective. To investigate the association between the presence of aPL and/or LA and all-cause mortality among end-stage renal disease (ESRD) patients with and without SLE. Methods. We included ESRD patients>18 years old followed at an urban tertiary care centre between 1 January 2006 and 31 January 2014 who had aPL measured at least once after initiating haemodialysis. All SLE patients met ACR/SLICC criteria. APL/LA+ was defined as aCL IgG or IgM>40 IU, anti-b2glycoprotein1 IgG or IgM≫40 IU or LA+. Deaths as at 31 January 2014 were captured in the linked National Death Index data. Time to death was defined from the first aPL measurement. Results. We included 34 SLE ESRD and 64 non-SLE ESRD patients; 30 patients died during the study period. SLE ESRD patients were younger [40.4 (12.5) vs 51.9 (18.1) years, P = 0.001] and more were women (88.2% vs 54.7%, P

KW - Antiphospholipid antibodies

KW - End stage

KW - Haemodialysis

KW - Lupus nephritis

KW - Renal disease

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84965075882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965075882&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kev423

DO - 10.1093/rheumatology/kev423

M3 - Article

C2 - 26705328

AN - SCOPUS:84965075882

VL - 55

SP - 817

EP - 825

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 5

ER -

Access to Document

10.1093/rheumatology/kev423